If a strategy of triple therapy is chosen in patients with concomitant AF and ACS, current guidelines strongly recommend against the use of the new P2Y12 inhibitors, the current standard of care after an ACS without AF. This evidence concerns the gene P2RY12 and atrial fibrillation.